Alexander Ginzburg, the scientific director of the Gamaleya National Research Center for Epidemiology and Microbiology, reported that the condition of the man with skin cancer who received the experimental vaccine showed significant improvement.
According to him, the cancer vaccine achieved a strong immune response that led to the elimination of the tumor in the first patient who received it, noting that the components of the vaccine work to stimulate the immune system to attack tumor cells.
It is reported that a 60-year-old man from the Kursk region, suffering from skin cancer, became on April 1st the first patient in Russia to receive the "Neoonkovak" vaccine, an mRNA vaccine specially designed for his condition and produced locally.
Ginsburg said: "The patient is feeling better. Today we can say that the vaccine has generated an immune response directed against a number of antigens specific to this patient's tumor, which are part of the mRNA vaccine. The immune response to the drug is very encouraging at the moment, as the patient has shown a good immune response."
He added that the patient showed a strong and remarkable response, which was represented in the production of the necessary cytokines, which help to attack the tumor and eliminate its cells after receiving treatment.
It should be noted that the “Neo Oncovac” vaccine, intended for the treatment of skin cancer, was developed by experts from the National Research Center for Radiological Medicine of the Russian Ministry of Health, in collaboration with the Gamaleya National Research Center for Epidemiology and Microbiology and the Blokhin National Research Center for Oncology.
This drug is used to treat adult patients with non-surgically resectable or metastatic skin cancer.
